



As of August 2022

RAISE Healthcare Initiative

Emerging biotechnologies are being developed to provide hope and healing for our neighbors who are vulnerable; we recognize that investors delight in the value new treatments can create for communities. But so often we hear stories about patients who are struggling with access and affordability.

Eventide believes that industry and investors are well-positioned to address these challenges.

We have the opportunity to leverage the power of purposeful investing to remove impediments to treatment—so that the healthcare system can truly promote health and patients can turn their imaginations to holistic wellbeing. As an extension of our Business 360® framework, our team is launching a new industry-specific initiative to motivate biotech companies towards sustainable strategy.



“Our vision is
a world where
medical innovation
is encouraged,
where *patient need*
is met with access,
and *value is*
justly rewarded.”



Eventide believes that industry and investors are best positioned to address drug pricing challenges.

GUIDING PRINCIPLES:

- **Transformational Medical Technologies**
We believe that treatments ought to meaningfully transform the patient's life expectancy and/or quality of life. We embrace companies pursuing treatments that significantly improve upon current therapies: either by way of reducing side effects/adverse events, increasing expected life years, or bettering quality of life; additionally, we seek treatments that will impact spending, driving down long-term systemic costs associated with a respective condition.
- **Commitment to Bioethical Principles and Practices**
We affirm organizational cultures and leadership with a commitment to bioethical alignment, promoting fidelity, veracity, and the principles outlined by the Belmont Report in animal studies, clinical trials, and service to the patient population.
- **Ethical and Effective Corporate Governance**
In accordance with Eventide's Business 360[®] diligence criteria, companies must promote ethical and effective corporate governance.
- **Sensible and Sustainable Pricing**
We recognize that a treatment's price ought to be sensible and sustainable, simultaneously respecting the healthcare ecosystem and allowing for innovative companies, their researchers, and their supporters to be remunerated fairly for their investment. We engage with companies to encourage responsible stewardship of capital to ensure that inappropriate costs will not be passed on to patients. We advocate for expanded cost effectiveness analyses to encourage ethical exploration within a range of prices.
- **Principled Corporate Strategy**
We hold that once a treatment is available to patients, companies should engage in principled corporate strategy with attention to avoiding Pharmacy Benefit Manager kickbacks, low-value reformulations, pay-for-delay, etc. We believe the company ought to look to "genericize" their product after a specified period of time.

When patients feel the financial strain of a treatment that does not reflect its value, society suffers and condemns the business.

STAKEHOLDER ENGAGEMENT – WHAT WE DO:

Current Areas of Impact: Biotech and Specialty Pharma Companies

- Hold our portfolio companies to industry-specific RAISE guiding principles, in research and development, governance, pricing, and corporate strategy.
- Engage our portfolio companies through our Business 360® framework, offering ongoing evaluation and recommendations with respect to RAISE guiding principles.
- Partner with portfolio companies to ensure just value of a treatment and appropriate capital allocation.
- Develop resources and tools for portfolio companies to operationalize an ethical, patient-centric culture.
- Identify strategic investments to reduce value extraction in the healthcare system.

OUR TIMELINE:

When it comes to drug pricing, there is no “quick fix” to the challenges stakeholders across the healthcare ecosystem face. By leveraging the Business 360® “Engage” approach, we hope to create long-term impact through collaboration with our portfolio partners and co-investors. Through our historic efforts in stakeholder and shareholder engagement, we’ve identified three strategic phases for the RAISE Healthcare initiative:



NOTES

1. Office for Human Research Protections (OHRP). “Read the Belmont Report.” HHS.gov, <https://www.hhs.gov/ohrp/regulations-and-policy/belmont-report/read-the-belmont-report/index.html>.
-

DISCLAIMER

This communication is provided for informational purposes only and expresses views of Eventide Asset Management, LLC (“Eventide”), an investment adviser. The RAISE (Restoration, Access, Innovation, Stewardship and Ethics) Healthcare Initiative is a part of Eventide’s Business 360® framework, to help promote sensible corporate strategy and pricing throughout the healthcare industry. There is no guarantee that Eventide’s RAISE Healthcare Initiative will achieve its intended results. This situation is evolving and circumstances may materially change in the future from what has been presented. This initiative will be funded through asset management fees and will therefore not be borne by investors, portfolio companies, or patients. There is no guarantee that any investment strategy will achieve its objectives, generate profits, or avoid losses. Eventide’s values-based approach to investing may not produce desired results and could result in underperformance compared with other investments. Any reference to Eventide’s Business 360® approach is provided for illustrative purposes only and indicates a general framework of guiding principles